Abstract

Purpose: Rhabdoid tumors are aggressive and incurable pediatric malignancies. INI1/hSNF5, a tumor suppressor biallelically deleted/inactivated in rhabdoid tumors, directly represses cyclin D1. Rhabdoid tumors and cells are exquisitely dependent on cyclin D1 for genesis and survival, suggesting that targeting the cyclin/cyclin-dependent kinase (cdk) axis may be an effective therapeutic strategy for these tumors. Because cdk inhibitors have not been used for preclinical or clinical testing on rhabdoid tumors, we investigated the effect of flavopiridol, a pan-cdk inhibitor with promising clinical activity, on rhabdoid tumors.

Experimental Design: The effect of flavopiridol on rhabdoid cells was tested in vitro using survival, cell cycle, and apoptosis assays. Its effect was assessed in vivo using xenografted rhabdoid tumor models. Immunoblot and immunohistochemical analysis was used to assess the effect of flavopiridol on cyclin D1 and p21 expression in vitro and in vivo, respectively.

Results: Nanomolar concentrations of flavopiridol inhibited rhabdoid cell growth (IC50 ~ 200 nmol/L), induced G1 and G2 arrest, and apoptosis in vitro in a concentration-dependent manner. These effects were correlated with the down-modulation of cyclin D1, up-regulation of p21, and induction of caspase 3/7 activities. Flavopiridol (at 7.5 mg/kg) significantly inhibited the growth of xenografted rhabdoid tumors, and its effect was correlated with the induction of p21 and down-modulation of cyclin D1.

Conclusions: Flavopiridol is effective in inducing cell cycle arrest and cytotoxicity in rhabdoid tumors. Its effects are correlated with the down-regulation of cyclin D1 and the up-regulation of p21. Flavopiridol is potentially a novel chemotherapeutic agent for rhabdoid tumors.

Rhabdoid tumors are rare but extremely aggressive pediatric malignancies that occur in the kidney (malignant rhabdoid tumors), brain/central nervous system (atypical teratoid and rhabdoid tumors), and soft tissues (extrarenal malignant rhabdoid tumors; ref. 1). Current therapies for rhabdoid tumors involve empirically selected combinations of highly toxic chemotherapeutic agents that are rarely curative (2, 3). Due to the extremely poor prognosis of this disease (15% 2-year survival rate; ref. 1), there is a dire need to develop novel therapies, preferably based on the understanding of the molecular mechanisms underlying the genesis and survival of rhabdoid tumors.

Molecular genetic studies have established that rhabdoid tumors are characterized by biallelic deletion/mutation of the INI1/hSNF5 tumor suppressor (1, 4). INI1 is a component of the SWI/SNF chromatin remodeling complex (5). Reintroduction of INI1 induces G0-G1 arrest in rhabdoid cells, directly represses cyclin D1 (6), and activates the cyclin-dependent kinase inhibitors (CDKIs), p16Ink4a and p21Cip1 (7). Rhabdoid tumors are dependent on cyclin D1 as shown both in vitro and in vivo; genetic ablation of cyclin D1 is sufficient to abrogate the formation of rhabdoid tumors in Ini1 +/− mice (8) and down-modulation of cyclin D1 by RNA interference induces G0-G1 arrest and apoptosis in rhabdoid tumor cell lines (9). Ini1 heterozygous mice develop a high frequency of spontaneous tumors that mimic the etiology, histopathology, and anatomic characteristics of atypical teratoid and rhabdoid tumors and extrarenal rhabdoid tumors (but not renal malignant rhabdoid tumor), as well as overexpress cyclin D1 (6, 8).

Cyclin D1 serves as a key sensor and integrator of extracellular stimuli in the early to mid-G1 phase of the cell cycle and overcomes the G1 restriction point (10). Cyclin D1 binds to and activates cyclin-dependent kinases, cdk4 and cdk6, which in turn phosphorylate Rb to inactivate it. Phosphorylation of Rb relieves E2F, activating its target gene transcription. In addition, overexpressed cyclin D1 sequesters p21Cip1 (cdk inhibitor), activating cyclin E-cdk2 holoenzyme and promoting G1-S transition. Recent studies using mouse models of breast cancer showed the importance of cdk-dependent functions of cyclin D1 for tumorigenesis (11, 12). Thus, it seems that targeting cdk function may recapitulate the effect of inhibiting
cyclin D1. Because rhabdoid tumors are dependent on cyclin D1, we tested the effectiveness of a pan-cdk inhibitor, flavopiridol, on these tumors.

Flavopiridol is the first broad spectrum cdk inhibitor to enter clinical trials. Recent clinical trials that used pharmacokinetics-derived schedules of flavopiridol administration have shown promising efficacy in inhibiting chronic lymphocytic leukemia (13). Flavopiridol induces cell cycle arrest and apoptosis at low nanomolar concentrations (IC$_{50}$ ~ 100 nmol/L) in vitro (14–17). Flavopiridol is a competitive inhibitor of multiple cyclins including cyclin D1, 2, 4, and 7 (18). Although its ability to inhibit cyclins D1, 2, 4, and 6 directly affects the function of cyclin/cdk complexes resulting in cell cycle arrest, its ability to inhibit cdk9 results in the inactivation of P-TEFb (cyclin T1/cdk9 complex), blocking RNA polymerase II–mediated transcription of many genes including cyclin D1 (18–20). Thus, it seems that flavopiridol is able to inhibit cyclin and cdk protein and activity levels through multiple mechanisms. Due to flavopiridol’s effect on various aspects of the cyclin/cdk axis, we tested its ability to indirectly inhibit tumor necrosis factor–induced nuclear factor-κB (17), and inhibits the activation of Akt, which leads to decreased cyclin D1 translation (21). Thus, it seems that flavopiridol is able to inhibit cell cycle arrest and apoptosis at concentrations of many genes including cyclin D1 (18–20). Our results, presented here for the first time, indicate that flavopiridol has strong inhibitory effects on the growth of rhabdoid cells and tumors, and that its effects are correlated with the down-modulation of cyclin D1.

### Materials and Methods

**Cell culture and drugs.** The rhabdoid tumor cell lines (INI1-/-) used, MON (4) and G401 (American Type Culture Collection) were maintained in RPMI supplemented with 10% fetal bovine serum. Twenty-four hours before plating cells for drug treatment, cultures were transferred to RPMI supplemented with 10% bovine serum pretreated with charcoal and dextran (HyClone). Flavopiridol was obtained through the Cancer Therapy Evaluation Program at National Cancer Institute (courtesy of Dr. Colevas) and the pan-caspase inhibitor, z-VAD-FMK, was purchased from Promega. Flavopiridol stock solution at 10 mmol/L concentration was prepared in DMSO. The working solution (3 mmol/L) and serial dilutions were prepared by diluting the stock solution with culture medium, such that the final concentration of DMSO was 0.03% in all the dilutions. **Analysis of drug effects on cell proliferation (MTS assay).** Aliquots of $8 \times 10^4$ cells were plated in 96-well plates and treated with serial dilutions of flavopiridol for 1, 2, or 5 days. Cell survival was determined using an MTS assay kit (CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit; Promega). Cell plating, drug treatment, and survival assay were done using the epMotion 5070 automated liquid handling system (Eppendorf).

**Cell cycle and apoptosis analysis.** Propidium iodide staining and fluorescence activated cell sorting (FACS) analysis was done as described previously (6). Data was elaborated using CellQuest Pro software (BD Biosciences). Apoptosis was assessed by gating for a sub-G$_1$ population during FACS and by caspase 3/7 activation using the Caspase-Glo 3/7 Assay Kit (Promega), as previously described (9).

**Statistical analysis.** Data was analyzed as previously described (9) using GraphPad Prism (GraphPad Software) to evaluate the numbers for each data group (e.g., controls and flavopiridol-treated) and one-way ANOVA or $t$-test was used.

**Immunoblot analysis.** Immunoblot analysis was carried out as described previously (6). The following antibodies were used: cyclin D1 (Lab Vision), cdk2 (Santa Cruz), cdk4 (Santa Cruz), p21 (Calbiochem), and glyceraldehyde-3-phosphate dehydrogenase (Chemicon). Chemiluminescence detection was achieved using SuperSignal West Pico Chemiluminescence Substrate (Pierce).

**Cancer Therapy: Preclinical**
Fig. 1. Flavopiridol inhibits rhabdoid cell survival and induces cell cycle arrest and apoptosis. A and B, survival curves of MON (A) and G401 (B) cells treated with increasing concentrations of flavopiridol for 1, 2, and 5 d and subjected to MTS assay. C and D, graphical representation to indicate time of exposure-dependent increase of flavopiridol-mediated cytotoxicity in MON (C) and G401 (D) cells. The values were derived from (A and B). E and F, cell cycle profile of diploid cell population determined by FACS analysis of MON (E) and G401 (F) cells treated with the indicated concentrations of flavopiridol for 48 h. G and H, percentage of MON (G) and G401 (H) cells at sub-G1 when exposed to flavopiridol for 48 h.
Flavopiridol induces cell cycle arrest and apoptosis in rhabdoid cells. To determine the mechanism of flavopiridol-induced effect on survival, cells were exposed to 100, 200, and 400 nmol/L of the drug for 2 days and subjected to FACS analysis. The results indicated that flavopiridol induced G2 arrest at 100 nmol/L ($P = 0.05$) and G1 arrest at 400 nmol/L ($P = 0.039$) in MON cells and specifically induced G1 arrest in G401 cells ($P = 0.047$ at 200 nmol/L and $P = 0.049$ at 400 nmol/L; Fig. 1E and F). Furthermore, analysis of the sub-G1 fraction of cells indicated that flavopiridol induced a dose-dependent increase in cell death in both cell types (Fig. 1G and H).

**Mechanism of cell death and cell cycle arrest induced by flavopiridol.** Flavopiridol induces cell death by both caspase-dependent and -independent mechanisms (21). To determine the mechanism of flavopiridol-induced cell death in rhabdoid cells, MON and G401 cells were treated with increasing concentrations of the drug for 2 days in the presence and absence of a pan-caspase inhibitor, z-VAD-FMK. FACS analysis was then carried out to determine the percentage of sub-G1 cells. The addition of a caspase inhibitor had no significant effect on the cell cycle profile (data not shown), but dramatically decreased the percentage of sub-G1 cells at all concentrations of the drug used, indicating that flavopiridol-induced cell death is caspase-dependent ($P = 0.0079$ for MON and 0.0028 for G401; Fig. 2A and B).

To determine if caspase 3/7 activities are induced upon flavopiridol treatment, cells were exposed to increasing concentrations of flavopiridol for various time points and subjected to the Caspase-Glo assay. The results of this analysis indicated that flavopiridol induced caspase 3/7 activity in MON and G401 cells in a dose- and time-dependent manner with activities observed at $\sim 12$ h posttreatment ($P < 0.0001$; Fig. 2C and D). These results indicate that flavopiridol induces caspase 3/7–mediated apoptosis in rhabdoid cells.

To determine the effect of flavopiridol on cell cycle regulators, we carried out immunoblot analyses of proteins isolated from MON and G401 cells treated for 2 days with different concentrations of flavopiridol. At 100 nmol/L, flavopiridol increased p21 levels in both MON and G401 cells (Fig. 2E). At 200 nmol/L, flavopiridol dramatically induced p21, and furthermore, led to a drastic decrease in cyclin D1 (Fig. 2F). Interestingly, 400 nmol/L of flavopiridol down-modulated both cyclin D1 and p21 levels. These results are intriguing and correlated with the effect of the drug on cell growth and cell cycle arrest. In particular, down-regulation of both cyclin D1 and p21 at 400 nmol/L of flavopiridol was consistent with the dramatic cell-killing effects seen at this concentration (Fig. 1A-D). These results indicate that flavopiridol induces cell cycle arrest and cytotoxicity by down-modulating cyclin D1, altering p21 levels, and up-regulating caspase 3/7 activities in rhabdoid cells.

**Development of xenograft mouse models of rhabdoid tumors.** Previously, we have been successful in generating xenografts of rhabdoid tumors by inoculating G401 cells s.c. in SCID mice (9). To test the generation of xenografts with MON cells, we inoculated these cells into SCID mice and found that no xenografts were implanted to form tumors (data not shown). These results prompted us to investigate the generation of xenografts from three commonly used rhabdoid cell lines (MON, G401, and STA-WT1) using various mouse strains. We used mice from four different genetic backgrounds including athymic nude, SCID, SCID-BEIGE, and ICR-SCID mice. The nude mice are T cell–deficient, but have normal B cell and natural killer cell functions (22). SCID mice are deficient for both T cells and B cells due to a defect in V(D)J recombination, however, have a leakiness in the expression of immunoglobulins and therefore exhibit low levels of immunoglobulins in $\sim 20\%$ of mice beginning at 12 weeks of age (23, 24). ICR-SCID mice are similar to SCID mice, except that they exhibit a significantly reduced incidence of spontaneous immunoglobulin production (23, 24). SCID-BEIGE mice are deficient for both B cells and T cells due to a defect in V(D)J recombination, as well as the presence of a Beige mutation that causes the impairment of cytotoxic T cells, macrophages, and selective natural killer cell functions (25).

Three different rhabdoid cell lines were inoculated into these four mouse strains, and tumor implantation and growth were monitored by measuring the tumor volume periodically. The growth characteristics of rhabdoid cells in different strains of mice varied significantly. MON cells implanted only in nude mice, in which they reached a maximum tumor volume of $\sim 100$ mm$^3$ and subsequently ceased to grow (Fig. 3A). Analysis of dissected xenografted tumors from these mice indicated the presence of a large degree of necrosis and fibrosis (data not shown). Other cell lines (G401, STA-WT1) although implanted efficiently in all four strains of mice, exhibited variability in terms of rate of growth, consistency, and interindividual variability (Fig. 3B-I). We observed that G401 cells, when inoculated into SCID mice, showed the most favorable growth pattern, exhibiting the least interindividual variability and a uniform tumor growth upon implantation (Fig. 3G). Thus, we chose xenografts derived from G401 cells inoculated into SCID mice to test the effect of flavopiridol in vivo.

Flavopiridol is effective in inhibiting xenografted rhabdoid tumors. To determine the effect of flavopiridol in vivo, G401 cells were inoculated into SCID mice. When the tumors were established and reached an average volume of $\sim 45$ mm$^3$, the mice were randomized into control and treatment groups. Mice in the control group received vehicle, whereas those in the treatment groups received 2.5 or 5.0 mg/kg of flavopiridol 5 days a week for 2 weeks. This was followed by an observation period of 3 to 4 weeks without drug treatment. Flavopiridol at 2.5 and 5.0 mg/kg had a minimal effect on xenografted tumor growth (Fig. 4A). Therefore, we treated another cohort of mice with 7.5 mg/kg of flavopiridol 5 days a week for 2 weeks and observed them for an additional 2 weeks without treatment. Flavopiridol at 7.5 mg/kg significantly inhibited xenografted tumor growth resulting in a reduction of average tumor volume compared with the controls ($P = 0.0096$; Fig. 4B). Analysis of tumor weights at the end of the treatment period indicated a significant decrease in average tumor weights consistent with the decrease in average tumor volume ($P = 0.039$; Fig. 4C). We found that flavopiridol treatment resulted in a slight weight loss in mice during the treatment period. However, these mice regained any lost weight during the posttreatment observation period (data not shown). These results indicate that 7.5 mg/kg of flavopiridol is effective in inhibiting xenografted rhabdoid tumor growth.

Flavopiridol treatment decreases cyclin D1- and increases p21-positive cells in rhabdoid tumor xenografts. Immunoblot analysis of rhabdoid tumor cells in vivo showed that the levels
of cyclin D1 and p21 are modulated by different concentrations of flavopiridol (Fig. 2E). To determine if flavopiridol-mediated reduction of tumor growth correlated with the regulation of cyclin D1 and p21 in vivo, tumors from three control and three flavopiridol-treated mice were analyzed for the expression of these two proteins by immunohistochemical analysis, at the termination of the experiment. The results indicated that although untreated control xenograft tumors exhibited pockets of strong nuclear staining of cyclin D1 (Fig. 5, 1-3), there was a significant reduction in intensity and percentage of cells positive for cyclin D1 in treated tumors (Fig. 5, 4-6). Interestingly, the ratio of nonneoplastic stromal cells to neoplastic cells greatly increased in flavopiridol-treated tumors, as compared with that of the control tumors (Fig. 5, compare 1-3 to 4-6).

Flavopiridol-treated tumors exhibited an increase in the number of cells positive for p21 when compared with that of the controls (Fig. 5, compare 7-9 to 10-12). Positive staining for...
Fig. 3. Comparative analysis of rhabdoid tumor xenograft growth using different rhabdoid cell lines and mouse strains. A, growth of MON cells as xenograft tumors when injected into nude mice; B-E, growth of STA-WT1 cells injected into SCID beige (B), SCID (C), nude (D), and ICR-SCID (E) mice; F-I, growth of G401 cells injected into SCID beige (F), SCID (G), nude (H), and ICR-SCID (I) mice. Please note different Y-axis scale for (A), in which MON cells inoculated into nude mice exhibited an inefficient growth pattern. Y-axes indicate tumor volume.
p21 was selectively observed in neoplastic cells of the treated tumors, whereas the stromal cells were largely negative (Fig. 5, 10-12). Together, these results indicate that the inhibitory effect of flavopiridol on xenografted tumors was correlated to a decrease in cyclin D1-positive cells and an increase in p21-positive cells.

Discussion

Rhabdoid tumors are highly aggressive and incurable pediatric malignancies. Despite a lack of standard or effective therapy for rhabdoid tumors, molecular biology of these tumors is well characterized (1). Understanding the detailed molecular mechanisms of rhabdoid tumorigenesis should pave the way to developing molecularly targeted therapies for rhabdoid tumors. Based on studies that have shown the essential role of cyclin D1 for rhabdoid tumorigenesis, we surmised that targeting the cyclin/cdk axis could be effective in inhibiting rhabdoid tumor growth (8, 9). Here, we report that the use of a pan-cdk inhibitor, flavopiridol, that both inhibits cdk activity and transcriptionally down-modulates cyclin D1, effectively inhibits rhabdoid tumor growth.

Our results indicate that low nanomolar concentrations of flavopiridol (IC$_{50}$, 150-200 nmol/L) have strong growth-inhibitory effects on rhabdoid cell lines in vitro. We found that increasing the time of exposure to flavopiridol in vitro did not change the IC$_{50}$ values, but dramatically increased cytotoxicity at concentrations >400 nmol/L (Fig. 1C and D). The exact reason for this increased cytotoxicity is unclear at this point. However, it is interesting to note that flavopiridol inhibited both cyclin D1 and p21 at 400 nmol/L concentrations (Fig. 2E). At lower concentrations (100-200 nmol/L), flavopiridol did not inhibit cyclin D1. It is therefore possible that increased cytotoxicity is related to the down-modulation of cyclin D1, as we found that inhibiting cyclin D1 in rhabdoid cells induces apoptosis in addition to G$_{1}$ arrest (9). Understanding the mechanistic basis of increased cytotoxicity of flavopiridol is valuable for improving its clinical efficacy.

Flavopiridol induced cell cycle arrest in a concentration- and cell type–dependent manner; whereas only MON cells exhibited G$_{2}$ arrest at 100 nmol/L of flavopiridol, both MON and G401 cells exhibited G$_{1}$ arrest at 400 nmol/L concentrations of flavopiridol (Fig. 1E). Flavopiridol differentially affected cyclin D1 and p21 levels—100 nmol/L of flavopiridol increased p21 and had no effect on cyclin D1; 200 nmol/L of flavopiridol moderately inhibited cyclin D1 and induced p21; and 400 nmol/L of flavopiridol reduced both cyclin D1 and p21 (Fig. 2E). We believe that concentration-dependent variability in biomarker expression and its correlation to flavopiridol-induced cytotoxicity in vivo may provide necessary insight to correlate its effect in vivo. For example, clinically achievable concentrations of flavopiridol are variable depending on the route, mode of administration, and other biological variables, which in turn, results in variability in the efficacy and in biomarker expression. This is reflected in the fact that although some reports correlate the up-regulation of p21 expression with the effect of flavopiridol (26–28), other reports correlate the down-regulation of p21 with the effects of flavopiridol (29–33). Our studies indicate that the differences in the biomarker expression could reflect the drug concentration achieved within tumors (also see below).

Our attempt to develop a xenograft model for rhabdoid tumors showed the variability with which rhabdoid cells implant in mouse strains with differing genetic backgrounds. It is intriguing to note that nude mice were less suitable for xenograft tumor formation when human rhabdoid tumor cell lines were used (Fig. 3). Previous studies have reported the use of nude mice for explants of human rhabdoid tumors (34, 35), indicating that the observed results are likely to represent a cell line–dependent phenomenon. Our studies indicate that it is...
possible to increase the efficiency of rhabdoid tumor implantation and growth based on the mouse strain, and that it might be possible to inhibit tumor growth by immunologic means.

Our results, for the first time, indicate that 7.5 mg/kg of flavopiridol is effective in significantly decreasing the growth of pre-established xenograft tumors. Analysis of biomarker expression in xenografts indicated that whereas cyclin D1 was down-regulated, p21 was up-regulated by flavopiridol treatment. Because the expression of cyclin D1 and p21 varied depending on the flavopiridol concentration in vitro, we surmise that we have been able to achieve only intermediate concentrations of flavopiridol (~200 nmol/L) in the xenograft tumors. Improving means to increase the concentration of drug within the tumor (≥400 nmol/L) is likely to further increase drug efficacy, which could then be monitored by the analysis of the two biomarkers, cyclin D1 and p21.

The drug concentrations and schedule of flavopiridol used in this study are based on previous preclinical reports (36). It was
reported that after daily (i.p. or i.v.) injections of 5 mg/kg of flavopiridol for 1 to 5 days, the plasma concentrations reached a maximum of ~7 μmol/L and declined in a biexponential manner to 0.1 μmol/L after 8 h (36). Furthermore, it was shown that after daily treatments with 7.5 mg/kg of flavopiridol by an i.p. or i.v. bolus for 5 consecutive days, 11 out of 12 advanced stage subcutaneous human HL60 xenografts underwent complete regression (36). Phase I clinical studies of flavopiridol have shown that peak concentrations and the area under the curve of flavopiridol were linear at various doses (37). Furthermore, the area under the curve and clearance were comparable between the 1-h infusion and 72-h CIV (continuous infusion) schedule and the area under the curve in mice at a dose of 5 mg/kg/d for 5 days was comparable with the area under the curve of flavopiridol administered over 1 h at the dose of 37.5 mg/m²/d for 5 days (Stinson, unpublished results in ref. 37). Assuming that pharmacokinetics is dose-proportional in mice (as it is in humans; ref. 37), then a 7.5 mg/kg dose in mice would be similar to a 56.25 mg/m²/d dose in humans (7.5/5 × 37.5 mg/kg).

Phase I trials of flavopiridol in human volunteers have indicated that toxicity profile, pharmacokinetics, and maximum tolerable dose were similar to that in adults (38). Furthermore, it was shown that the maximum tolerable dose of flavopiridol in children was 62.5 mg/m²/d (without prophylaxis) and 80 mg/m²/d (with prophylaxis) when administered for 3 days (38), indicating that the use of flavopiridol in rhabdoid patients, a largely pediatric population, is feasible.

Flavopiridol has shown efficacy in clinical trials of chronic lymphocytic leukemia, in which a pharmacokinetics-derived schedule of administration were used (13). The schedule involved a 30-min loading dose, followed by 4 h of infusion administered weekly for 4 to 6 weeks. Using these novel clinical protocols, a long-term high-plasma concentration of flavopiridol (~1.5 μmol/L), could be achieved, which is above the concentration of the drug required to inhibit the tumor growth as indicated in preclinical models. These studies suggest that the concentration of flavopiridol required to inhibit rhabdoid tumor growth could be clinically achieved.

The aggressive and incurable nature of rhabdoid tumors corroborates the need to develop a targeted and effective therapy for these tumors. Our results indicate that targeting the cyclin/cdk axis is a novel and effective approach in achieving this goal. Our previous studies using farnesitide showed efficacy in inhibiting rhabdoid tumor growth in correlation with the inhibition of cyclin D1 (9). In this report, we show, for the first time, that the pan-cdk inhibitor flavopiridol is effective in inhibiting rhabdoid tumor growth in vitro and in vivo. These findings strengthen our hypothesis that targeting the cyclin/cdk axis is an effective means of therapy against rhabdoid tumors. We therefore propose that flavopiridol should be tested in children with rhabdoid tumors in which there is a dire need for an effective therapy.

Acknowledgments

We thank Drs. Goldman and Prasad at AECOM for useful discussions, Dr. Colevas at the Cancer Therapy Evaluation Program, National Cancer Institute for providing flavopiridol, and Dr. Zhikai Zhang for initiating the flavopiridol project on rhabdoid cell lines in the laboratory.

References


Rhabdoid Tumor Growth is Inhibited by Flavopiridol

Melissa E. Smith, Velasco Cimica, Srinivasa Chinni, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/14/2/523

Cited articles
This article cites 38 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/14/2/523.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/14/2/523.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/14/2/523.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.